Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.

Clinical pharmacology and therapeutics - 1 Nov 2017

Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, Amstutz U, Largiader C R

Abstract excerpt

An important concern with the anticancer drug capecitabine (Cp), an oral prodrug of 5-fluorouracil, are dose-limiting adverse effects, in particular hand-foot syndrome (HFS) and diarrhea. Here we evaluated the association of genetic variability in all enzymes of the Cp-activation pathway to 5-fluorouracil with Cp-related early-onset toxicity in 144 patients receiving Cp. We identified a haplotype encompassing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboxylic Ester Hydrolases

Share to Cohort Studies

Share to Forecasting

Share to Neoplasms

Share to Prodrugs

Share to Severity of Illness Index

Source

Identifiers

PMID: 28139840
DOI: 10.1002/cpt.641

Genes

CES1
CDA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.PMID 28139840Read ↗

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYDSemantic proximity Read ↗

Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.Semantic proximity Read ↗

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.Semantic proximity Read ↗

Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.Semantic proximity Read ↗

A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.Semantic proximity Read ↗

The role of pharmacogenetics in capecitabine efficacy and toxicity.Semantic proximity Read ↗

Pharmacogenomic assessment of carboxylesterases 1 and 2.Semantic proximity Read ↗

Pharmacogenomics of fluorouracil -based chemotherapy toxicity.Semantic proximity Read ↗

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer.Semantic proximity Read ↗

Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity.Semantic proximity Read ↗

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.Semantic proximity Read ↗

Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.